Watch how cancer survivors struggle to resume a normal life
11 Apr 2016
On 31 March and 1 April 2016, EORTC held its 2nd Summit on Cancer Survivorship. You can now watch the presentations and panel discussions that addressed both societal and health issues that cancer survivors face to resume a normal life.
Thursday 31 March 2016 – Societal Aspects
- Welcome (F. Meunier)
- Keynote lecture: Current policies and perspectives on cancer survivors employment (B. Van Damme deputy Head of cabinet of Belgium’s Minister of Public health and Social affairs M. De Block)
- Keynote lecture: Cancer as inspiration: re-interpreting the “C” word”! (Sir P. Jonas)
Session 1: A newly discovered reality (Chairs: P. O’Donnell & R. Sullivan)
- Keynote lecture: Quantify the magnitude of long-term cancer survivors in Europe (A. Waldmann)
- Keynote lecture: Economic burden of cancer across the European Union and unemployment (R. Sullivan)
- Panel discussion: The awareness of the societal challenges faced by cancer survivors and the policy support in EU (J. Kelly, Chairs & Speakers of the Session)
Session 2: Accessibility to Job, insurance and mortgage (Chairs: I. Lebrocquy & R. Stupp)
- Keynote lecture: Build a life after cancer: Discrimination issues & answers (E. Van Laer)
- Panel discussion (Moderator: A. Jack): Job, Insurance, Mortgage (I. Klingmann, I. Kössler, M. Massart, S. Narbutas, N. Van den Cruyce, M. Vanden Wijngaert, M. Vermaerke, Chairs & Speakers of the Session)
Session 3: Specificities related to survivors of childhood and young adolescent cancer (Chairs: F. Baron & G. Vassal)
- Quality of survivorship, a major goal in the SIOPE strategic plan (G. Vassal)
- Childhood cancer survivors: Facts and needs (G. Vassal)
- Access to recommendations, follow up and care: the survivorship passport (S. Essiaf)
- Long-term follow-up studies: The EORTC Leukemia Group Experience (C. Piette)
- Panel discussion (Chairs & Speakers of the Session)
- Conclusion (F. Meunier)
Friday 1 April 2016 – Medical Aspects
Session 4: Lifestyle after cancer – How to intervene? (Chairs: E.C. Moser & S. Narbutas)
- A patient’s perspective of cancer survivorship (I. Verdonck-de Leeuw )
- Role (early) interventions, life style (J. Maher)
- Growing up with cancer – Childhood cancer survivorship (C. Parsons)
- Panel discussion (Chairs & Speakers of the Session)
Session 5: Data collection and legal issues – Challenges (Chairs: J. Bogaerts & J. Reijneveld)
- Mobile, social and tech are disrupting healthcare. Get ready! (V. Keunen)
- Innovation radiotherapy data collection (P. Meijnders)
- European legal framework on collection and sharing of data (M. Verlinden)
- Panel discussion (L. Van Eycken, Chairs & Speakers of the Session)
Session 6: Lifestyle after cancer – How to measure? (Chairs: G. Katz & L. van de Poll-Franse)
- Infertility and sexuality after cancer treatment (R. Nout)
- 10 million cancer survivors in Europe (L. van de Poll-Franse)
- How to measure cognitive changes following cancer & cancer treatment? (S. Schagen)
- Is germline engineering acceptable for cancer survivors? (G. Katz)
- Panel discussion (P. Hoogendoorn, Chairs & Speakers of the Session)
Session 7: The EORTC survivorship taskforce, the commitment, vision and future perspectives (Chairs: L. Liu & A. Waldmann)
- Patient voice (B. Roman)
- The EORTC survivorship taskforce (L. Liu)
- Boost no-Boost trial: 20 years of follow-up of Breast Cancer (E.C. Moser)
- Panel discussion (Chairs & Speakers of the Session)
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023